{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008070","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.067035+00:00","generated_at":"2026-06-02T01:03:54.261211+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024","bullets":["Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.","Cash and equivalents $32.4M as of March 31, 2024, up from $21.6M at Dec 31, 2023; runway into Q3 2025.","FDA cleared IND for APR-1051 (WEE1 inhibitor) in March 2024; Phase 1 ACESOT-1051 trial expected to start June 2024.","Phase 1/2a ATRN-119 (ATR inhibitor) trial continues; dose escalation completion expected 4Q 2024; initial efficacy data possible 2H 2024.","Completed $16M upfront private placement in March 2024 with potential for additional $18M warrants; appointed Nadeem Mirza as CMO effective May 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008070","json":"https://secwatch.observer/filing/0001558370-24-008070.json","markdown":"https://secwatch.observer/filing/0001558370-24-008070.md","text":"https://secwatch.observer/filing/0001558370-24-008070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/0001558370-24-008070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/apre-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:03:54.261211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51747302b33c5ddd569dd3cf5a739f9367fa34a9","claim":"Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/0001558370-24-008070-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}